clobetasol propionate
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OLUX | — | 2002-12-20 | fda.gov ↗ |
| Label expansion | US (FDA) | TEMOVATE E | — | 1996-05-03 | fda.gov ↗ |
| Approved | US (FDA) | TEMOVATE | — | 1985-12-27 | fda.gov ↗ |
Trials 39 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02973776 | Dec 2016 → Feb 2017 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02355639 | Jan → Apr 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01946386 | Sep → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01381445 | Apr → Jul 2011 | atopic eczema | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01043224 | Jan → Mar 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00864240 | Oct 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03847389 | Sep 2019 → May 2020 | atopic eczema | Hill Dermaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07100613 | Sep 2024 → Oct 2027 expected | lichen planus, oral, mouth mucosa disorder | University of Palermo | Recruiting | No outcome recorded |
| Phase 2 | NCT06363539 | Sep 2022 → Mar 2023 | pyogenic granuloma | Children Hospital and Institute of Child Health, Lahore | Completed | No outcome recorded |
| Phase 2 | NCT04089735 | Aug 2019 → Apr 2020 | — | Formosa Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03592342 | Jun 2018 → Dec 2019 | lichen planus, oral | Dermtreat | Completed | No outcome recorded |
| Phase 2 | NCT02368886 | Mar 2015 → Sep 2017 | colon adenocarcinoma, rectum adenocarcinoma | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 2 | NCT02131324 | May 2014 → Apr 2016 | psoriasis | Promius Pharma, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01567215 | May 2012 → Feb 2014 | — | Pernille Pedersen | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT05724446 | Dec 2022 → Dec 2025 overdue | cataract | Salvat | Recruiting | No outcome recorded |
| Phase 3 | NCT05364515 | Dec 2021 → Feb 2024 | vulvar lichen sclerosus | Fundación Eduardo Anitua | Withdrawn | No outcome recorded |
| Phase 3 | NCT04246801 | Jun 2020 → May 2021 | cataract | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT04249076 | Jun 2020 → Apr 2021 | cataract | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT02573883 | Oct 2015 → Sep 2019 | vulvar lichen sclerosus | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01235442 | Sep 2010 → Oct 2011 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00862654 | Mar 2009 → Feb 2010 | seborrheic dermatitis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT02313870 | Jan 2008 → May 2015 | bullous pemphigoid | University Hospital, Montpellier | Completed | No outcome recorded |
| Phase 3 | NCT00400725 | Sep 2006 → Aug 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT01453686 | Aug 2002 → Aug 2003 | alopecia areata | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT03926377 | Dec 2020 → Oct 2025 | bullous pemphigoid, osteoporosis | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 4 | NCT02733874 | Apr 2015 → Apr 2016 | psoriasis | First Hospital of China Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02360202 | Feb 2015 → Feb 2017 | bullous pemphigoid | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 4 | NCT01893567 | Jul → Oct 2013 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01012713 | Jun 2010 → Dec 2014 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT01111981 | Oct 2009 → Feb 2010 | alopecia | Callender Center for Clinical Research | Unknown | No outcome recorded |
| Phase 4 | NCT00988637 | Oct 2009 → Mar 2010 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00852761 | Mar → Jun 2009 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00828464 | Oct 2008 → Jan 2009 | hand dermatosis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00842153 | Nov → Dec 2007 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07278999 | Dec 2025 → Oct 2026 expected | lichen planus, oral, multiple mucosal neuroma | Medical University of Silesia | Recruiting | No outcome recorded |
| — | NCT07641725 | Nov 2025 → Sep 2026 expected | pemphigus vulgaris | Damascus University | Recruiting | No outcome recorded |
| — | NCT06856590 | Feb → Sep 2025 | hand-foot syndrome | Gazi University | Completed | No outcome recorded |
| — | NCT03779360 | Oct 2018 → Feb 2019 | dermatitis | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| — | NCT02492373 | Feb 2015 → May 2016 | hyperpigmentation of the skin, lentigo | Mahidol University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 42 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07398807 Comparator | Aug 2025 → Feb 2026 overdue | vitiligo | Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan | Recruiting | No outcome recorded |
| Phase 0 | NCT06555497 Comparator | Jan 2022 → Dec 2023 | psoriasis | Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT05885269 Comparator | Nov 2022 → Apr 2023 | alopecia areata | Combined Military Hospital Abbottabad | Completed | No outcome recorded |
| Phase 1 | NCT03878771 Comparator | Mar → Apr 2019 | Stevens-Johnson syndrome, mucous membrane pemphigoid, pemphigus vulgaris | Beni-Suef University | Completed | No outcome recorded |
| Phase 1 | NCT03758365 Comparator | Nov 2018 | vascular disorder | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02936492 Comparator | Oct 2016 → Apr 2017 | psoriasis | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT02940002 Comparator | Oct 2016 → Jan 2017 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02392130 Comparator | Mar → Jun 2015 | connective tissue disorder, skin disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02376049 Comparator | Feb → Jul 2015 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05706870 Comparator | Dec 2022 → Jan 2024 | psoriasis | GEN İlaç ve Sağlık Ürünleri A.Ş. | Completed | No outcome recorded |
| Phase 2 | NCT03386643 Comparator | Nov 2017 → Apr 2018 | lichen planus, oral | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT03026478 Comparator | May 2016 → Mar 2018 | lichen planus, oral | Garlapati Komali | Unknown | No outcome recorded |
| Phase 2 | NCT01126255 Comparator | Mar 2011 → Jul 2014 | vulvar lichen sclerosus | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 2 | NCT00757874 Comparator | Apr 2006 → Nov 2009 | vulvar lichen sclerosus | Deana Funaro | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05243563 Background | Apr 2022 → Jun 2024 | vulvar lichen sclerosus | University of South Alabama | Terminated | No outcome recorded |
| Phase 2/3 | NCT04364555 Comparator | May 2020 → Jul 2024 overdue | lichen planus, oral | Malmö University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01282515 Comparator | Aug 2011 → Oct 2014 | lichen planus | Oslo University Hospital | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04649697 Comparator | Dec 2020 → Dec 2023 | rheumatoid arthritis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT00658788 Comparator | Mar 2008 → Jan 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00438399 Comparator | Feb 2007 → Jan 2008 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07666620 Comparator | Oct 2026 → Apr 2027 expected | hypertrophic lichen planus | Noor Aziz | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06042647 Comparator | Jul → Nov 2023 | psoriasis | Dermatology Consulting Services, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT04951206 Comparator | Mar 2022 → Apr 2025 | vulvar lichen sclerosus | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03535233 Comparator | Mar 2016 → Jun 2017 | alopecia areata | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02487212 Comparator | Apr 2014 → Apr 2015 | reactive cutaneous fibrous lesion | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT01745133 Comparator | Jan 2013 → May 2014 | psoriasis | Leon Kircik, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01323673 Comparator | Nov 2010 → Mar 2011 | dermatitis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT01703325 Comparator | Nov 2010 → Mar 2012 | psoriasis | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00881868 Comparator | Apr → Dec 2009 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00733954 Comparator | Aug 2007 → Apr 2008 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00437255 Comparator | Aug 2006 → Jun 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00436540 Comparator | Mar 2006 → Jan 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07240389 Comparator | Dec 2025 → Dec 2026 expected | vulvar lichen sclerosus | Milosz Pietrus | Not yet recruiting | No outcome recorded |
| — | NCT07536737 Comparator | Sep 2021 → Jan 2023 | lichen planus, oral | Medical University of Bialystok | Completed | No outcome recorded |
| — | NCT05818618 Comparator | Mar 2020 → Jul 2023 | lichen planus, oral | University of Catania | Completed | No outcome recorded |
| — | NCT03983460 Comparator | Mar 2020 → Jun 2021 | atopic eczema | Association pour la Recherche Clinique et Immunologique | Unknown | No outcome recorded |
| — | NCT03926299 Comparator | Jul 2019 → Jul 2024 | vulvar lichen sclerosus | Prof. Dr. Volker Viereck | Completed | No outcome recorded |
| — | NCT04673916 Comparator | Jun 2019 → Feb 2020 | lichen planus, oral, preneoplastic lesion | University of Messina | Completed | No outcome recorded |
| — | NCT03320460 Comparator | Nov 2018 → Nov 2020 | lichen planus, oral | University of Nove de Julho | Unknown | No outcome recorded |
| — | NCT02416531 Comparator | Jan 2015 → Aug 2016 | vulvar lichen sclerosus | Daniela de Fátima Teixeira da Silva | Completed | No outcome recorded |
| — | NCT01591785 Comparator | Jan → Aug 2012 | atopic eczema, hand dermatosis | Gary Goldenberg | Completed | No outcome recorded |
| — | NCT00189397 Background | Feb 2003 → Oct 2005 | toxic dermatosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 83 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clobetasol propionate | “In a study of 1254 subjects treated with clobetasol propionate spray 0.05% as monotherapy twice daily for four weeks, 35.7% of patients achieved clearance and 37.3% of patients...” NCT01012713 ↗78“The primary objective of this study was to compare the therapeutic efficacy of clobetasol propionate 0.05% oral gel versus an anti-inflammatory mouthwash in an oral solution...” NCT04673916 ↗ “the patients will be randomly treated with azathioprine 300 mg per week or azathioprine 100 mg a day orally along with topical clobetasol propionate 0.05% w/w and oral...” NCT00189397 ↗ “Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05%...” NCT03983460 ↗ “The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a...” NCT00438399 ↗ “Clobetasol propionate 0.05% (Clobederm) is applied topically to oral lichen planus lesions twice daily for a period of 5 weeks, according to standard clinical practice.” NCT07536737 ↗ “DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis” NCT02131324 ↗ “A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus.” NCT00757874 ↗ “Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%” NCT01893567 ↗ “This study is being conducted to obtain efficacy and tolerability data for two clobetasol propionate therapies in the treatment of plaque-type psoriasis.” NCT00852761 ↗ “The aim of this study was to compare the efficacy of PBM (660 nm) with corticosteroid therapy with clobetasol propionate 0.05% for the treatment of OLP.” PMID 30297352 ↗ Oct 2018 “Clobex® shampoo (Clobetasol Propionate) 0.05 percent (%) weight by weight (W/W) topically to the scalp once daily (twice a week) for 4 weeks” NCT00400725 ↗ “To evaluate clobetasol propionate ophthalmic suspension (CPN) as treatment for inflammation and pain after cataract surgery.” PMID 41329923 ↗ May 2026 “A mucoadhesive patch containing clobetasol propionate 0.05%. Applied once daily for 30 days to the oral lesion.” NCT07100613 ↗ “Clobetasol Propionate 0.05% in orabase will be applied to 10 control patients 3 times per day for one week.” NCT03878771 ↗ “To determine the dose-response relationship for Clobex TM (clobetasol propionate) Lotion, 0.05%.” NCT00864240 ↗ “twice-daily topical application of clobetasol propionate 0.05% foam to hands/feet for 14 days” PMID 25053981 ↗ Jul 2014 “Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.” NCT03926377 ↗ “self-applied topical steroid therapy using clobetasol propionate 0.05%” NCT05243563 ↗ “Patients were treated with a topic gel of clobetasol propionate 0,05%” NCT05818618 ↗ “calcitriol ointment 3µg/g and clobetasol propionate spray 0.05%” NCT00988637 ↗ “Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream” NCT02973776 ↗ |
| Known as | Clobederm | “Clobetasol propionate 0.05% (Clobederm) is applied topically to oral lichen planus lesions twice daily for a period of 5 weeks, according to standard clinical practice.” NCT07536737 ↗ |
| Known as | Clobetasol | “OBJECTIVE: To assess the effect of clobetasol propionate ophthalmic nanoemulsion, 0.05% (clobetasol) on ocular inflammation and eye pain associated with cataract surgery.” PMID 42192627 ↗ May 20261“Clobetasol, a high-potency corticosteroid, has been shown to significantly reduce the severity of HFSR when used preemptively rather than reactively.” NCT06856590 ↗ |
| Known as | Clobetasol 17-propionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05706870 ↗ |
| Known as | Clobex | “The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a...” NCT00438399 ↗2“Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%” NCT01893567 ↗ “Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05%” NCT00988637 ↗ |
| Known as | Clobex Shampoo | “Clobex® shampoo (Clobetasol Propionate) 0.05 percent (%) weight by weight (W/W) topically to the scalp once daily (twice a week) for 4 weeks” NCT00400725 ↗ |
| Known as | Clobex TM | “To determine the dose-response relationship for Clobex TM (clobetasol propionate) Lotion, 0.05%.” NCT00864240 ↗ |
| Known as | CPN | “To evaluate clobetasol propionate ophthalmic suspension (CPN) as treatment for inflammation and pain after cataract surgery.” PMID 41329923 ↗ May 2026 |
| Known as | Dermoval | “Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.” NCT03926377 ↗1“Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream” NCT02973776 ↗ |
| Known as | Dermoval 0.05% cream | “Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05%...” NCT03983460 ↗ |
| Known as | Dermovate | “Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.” NCT01567215 ↗3“Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream” NCT02973776 ↗ “Clobetasol Propionate 0.05% Cream (Dermovate)” NCT07240389 ↗ |
| Known as | Dermovate cream | “Clobetasol propionate 0.05%(Dermovate cream) in orabase” NCT03878771 ↗ |
| Known as | Olux-E | “Clobetasol propionate foam 0.05% (Olux-E), a Class 1 corticosteroid, is formulated in an ethanol free petrolatum base that provides the benefits of a super-potent...” NCT01323673 ↗1“Olux-E (clobetasol propionate 0.05%) foam.” NCT00852761 ↗ |
| Known as | Propionate clobetasol | “Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days.” NCT03320460 ↗ |
| Known as | Rivelin-CLO patches | “Randomized, double-blind, placebo-controlled, parallel group clinical study with 3 active dose arms (Rivelin®-CLO patches) and one placebo arm (Rivelin® plain patch).” NCT03592342 ↗ |
| Action | Inhibit | “This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.” NCT03779360 ↗ |
| Modality | Small molecule | “two different forms of a topical steroid (clobetasol propionate)” NCT00852761 ↗ |
| Route | Topical | “topical clobetasol propionate 0.05% w/w” NCT00189397 ↗ |